# Breakthroughs in Alzheimer’s Treatment: ALZ-801 Shines!

Newsy: Alzheimer’s News Weekly
Published: 2026-02-09T13:30:00.216Z
Source: https://newsyai.com/edition/6a8cec19-4b3f-4db5-b251-b3bb9599a07d
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# Alzheimer’s Treatment Briefing
Coverage period: February 3–9, 2026 (United States)

Below are the most meaningful, truly new developments from the past 7 days, ranked by impact on treatment and access.

1) Oral Alzheimer’s pill ALZ-801 shows blood-tau drops tied to better thinking and brain protection
- Overview
  - Alzheon reported new analyses across its Phase 3 (APOLLOE4) and Phase 2 studies of the oral drug valiltramiprosate/ALZ-801. Bigger decreases in the blood marker p‑tau217 were linked with better cognition, daily function, and less hippocampal shrinkage in people with early Alzheimer’s. The update also confirmed very high rates of Alzheimer’s biology in enrolled participants using an FDA‑cleared blood test threshold. Published February 3, 2026. [Business Wire/Alzheon press release](https://www.biospace.com/press-releases/alzheon-reports-plasma-biomarker-results-from-phase-3-and-2-studies-of-valiltramiprosate-alz-801-validating-its-first-in-class-mechanism-of-action-and-underscoring-benefits-in-cognition-function-and-brain-volume-protection-in-alzheimers-patients), [Company newsroom](https://alzheon.com/press-releases/). ([biospace.com](https://www.biospace.com/press-releases/alzheon-reports-plasma-biomarker-results-from-phase-3-and-2-studies-of-valiltramiprosate-alz-801-validating-its-first-in-class-mechanism-of-action-and-underscoring-benefits-in-cognition-function-and-brain-volume-protection-in-alzheimers-patients?utm_source=openai))
- Why this matters
  - A safe pill that slows Alzheimer’s biology and tracks with thinking and daily function would be a major step beyond today’s infusion/injection options. The p‑tau217 link also strengthens use of simple blood tests to monitor if a treatment is hitting the disease process in real patients. ([biospace.com](https://www.biospace.com/press-releases/alzheon-reports-plasma-biomarker-results-from-phase-3-and-2-studies-of-valiltramiprosate-alz-801-validating-its-first-in-class-mechanism-of-action-and-underscoring-benefits-in-cognition-function-and-brain-volume-protection-in-alzheimers-patients?utm_source=openai))

2) Nature publishes state‑of‑the‑art roadmap for Alzheimer’s blood and spinal fluid tests
- Overview
  - A high‑level review in Nature (published February 4, 2026) summarizes which biofluid markers (like p‑tau217 and Aβ42/40) are ready for clinic use, how accurate they are, and how to combine them with imaging when needed. It’s a practical guide for diagnosis and for routing the right people to treatment. [Nature article](https://www.nature.com/articles/s41586-025-10018-w). ([nature.com](https://www.nature.com/articles/s41586-025-10018-w?utm_source=openai))
- Why this matters
  - Clear guidance from a top journal helps clinics expand “blood‑first” triage. That means faster, cheaper confirmation of Alzheimer’s changes and quicker starts on disease‑slowing drugs where appropriate. ([nature.com](https://www.nature.com/articles/s41586-025-10018-w?utm_source=openai))

3) U.S. boosts federal Alzheimer’s funding: +$100M for NIH research and record support for public‑health programs
- Overview
  - On February 3, 2026, the FY2026 spending package was signed, adding $100M for NIH Alzheimer’s/dementia research (total ≈$3.9B) and $41.5M for CDC’s BOLD program (risk reduction, early detection, caregiver support). [Alzheimer’s Association announcement](https://www.alz.org/news/2026/100-million-dollar-alzheimers-dementia-research-signed-law). ([alz.org](https://www.alz.org/news/2026/100-million-dollar-alzheimers-dementia-research-signed-law?utm_source=openai))
- Why this matters
  - More funding accelerates next‑gen treatments (including oral and anti‑tau options) and strengthens the care “plumbing” that determines who actually gets diagnosed, treated, and supported. ([alz.org](https://www.alz.org/news/2026/100-million-dollar-alzheimers-dementia-research-signed-law?utm_source=openai))

4) Blood‑test momentum for clinical triage continues
- Overview
  - Quest shared performance data for two upcoming AD‑Detect panels (Aβ42/40 + p‑tau217 ± ApoE). In a symptomatic clinic population, both versions hit 91% sensitivity and 91% specificity with low “indeterminate” rates; the three‑marker version is slated to launch in Q1 2026. [Quest Diagnostics release](https://ir.questdiagnostics.com/press-releases/press-release-details/2025/New-Study-Demonstrates-Accuracy-of-Two-Quest-AD-Detect-Tests-for-Alzheimers-Disease-Diagnosis/default.aspx). ([ir.questdiagnostics.com](https://ir.questdiagnostics.com/press-releases/press-release-details/2025/New-Study-Demonstrates-Accuracy-of-Two-Quest-AD-Detect-Tests-for-Alzheimers-Disease-Diagnosis/default.aspx?utm_source=openai))
- Why this matters
  - As more regulated blood tests reach routine labs, primary‑care teams can confirm Alzheimer‑type brain changes faster and refer the right patients for treatment or imaging—reducing bottlenecks and costs. ([ir.questdiagnostics.com](https://ir.questdiagnostics.com/press-releases/press-release-details/2025/New-Study-Demonstrates-Accuracy-of-Two-Quest-AD-Detect-Tests-for-Alzheimers-Disease-Diagnosis/default.aspx?utm_source=openai))

Quick hits (new and useful, but secondary impact)
- Leqembi at‑home “start on injections” path under FDA review got fresh coverage this week; decision expected May 24, 2026. If cleared, patients could begin therapy at home instead of starting with months of clinic infusions. Plan clinic workflows now. [Alzheimer’s News Today explainer](https://alzheimersnewstoday.com/news/fda-mulls-expanded-home-injectionsalzheimers-drug-leqembi/). ([alzheimersnewstoday.com](https://alzheimersnewstoday.com/news/fda-mulls-expanded-home-injectionsalzheimers-drug-leqembi/?utm_source=openai))
- Research community reminder: the Tau Global Conference (Washington, DC + online) is May 14–15, 2026; abstract deadline is February 18 (extended to February 23 for ISTAART members). Expect add‑on/combination tau‑targeting strategies to feature prominently. [Alzheimer’s Association Tau Conference](https://www.alz.org/tau). ([alz.org](https://www.alz.org/tau?utm_source=openai))

What this means for care right now
- Expand blood‑first triage
  - Use FDA‑cleared blood biomarkers to identify who likely has Alzheimer’s changes and should move on to imaging and treatment consults. This speeds access and reduces unnecessary scans. ([apnews.com](https://apnews.com/article/ad3cffe0bd540accf47e8ee105b439a9?utm_source=openai))
- Watch the oral pipeline
  - Track ALZ‑801’s next steps. If confirmatory trials deliver, an effective pill—especially for people with APOE4—could complement or, for some, substitute for infusion/injection therapy. ([biospace.com](https://www.biospace.com/press-releases/alzheon-reports-plasma-biomarker-results-from-phase-3-and-2-studies-of-valiltramiprosate-alz-801-validating-its-first-in-class-mechanism-of-action-and-underscoring-benefits-in-cognition-function-and-brain-volume-protection-in-alzheimers-patients?utm_source=openai))
- Prepare for home initiation of lecanemab
  - If the FDA approves starting treatment with at‑home injections on May 24, 2026, set up training, monitoring, and MRI‑safety protocols now to launch smoothly. ([alzheimersnewstoday.com](https://alzheimersnewstoday.com/news/fda-mulls-expanded-home-injectionsalzheimers-drug-leqembi/?utm_source=openai))

Sources
- Alzheon cross‑trial biomarker update (February 3, 2026): [BioSpace](https://www.biospace.com/press-releases/alzheon-reports-plasma-biomarker-results-from-phase-3-and-2-studies-of-valiltramiprosate-alz-801-validating-its-first-in-class-mechanism-of-action-and-underscoring-benefits-in-cognition-function-and-brain-volume-protection-in-alzheimers-patients); [Alzheon newsroom](https://alzheon.com/press-releases/). ([biospace.com](https://www.biospace.com/press-releases/alzheon-reports-plasma-biomarker-results-from-phase-3-and-2-studies-of-valiltramiprosate-alz-801-validating-its-first-in-class-mechanism-of-action-and-underscoring-benefits-in-cognition-function-and-brain-volume-protection-in-alzheimers-patients?utm_source=openai))
- Nature review on biofluid biomarkers (published February 4, 2026): [Nature](https://www.nature.com/articles/s41586-025-10018-w). ([nature.com](https://www.nature.com/articles/s41586-025-10018-w?utm_source=openai))
- Federal funding increase (February 3, 2026): [Alzheimer’s Association](https://www.alz.org/news/2026/100-million-dollar-alzheimers-dementia-research-signed-law). ([alz.org](https://www.alz.org/news/2026/100-million-dollar-alzheimers-dementia-research-signed-law?utm_source=openai))
- Quest AD‑Detect performance and Q1 2026 launch: [Quest Diagnostics](https://ir.questdiagnostics.com/press-releases/press-release-details/2025/New-Study-Demonstrates-Accuracy-of-Two-Quest-AD-Detect-Tests-for-Alzheimers-Disease-Diagnosis/default.aspx). ([ir.questdiagnostics.com](https://ir.questdiagnostics.com/press-releases/press-release-details/2025/New-Study-Demonstrates-Accuracy-of-Two-Quest-AD-Detect-Tests-for-Alzheimers-Disease-Diagnosis/default.aspx?utm_source=openai))
- Leqembi at‑home initiation review and May 24, 2026 PDUFA date: [Alzheimer’s News Today](https://alzheimersnewstoday.com/news/fda-mulls-expanded-home-injectionsalzheimers-drug-leqembi/). ([alzheimersnewstoday.com](https://alzheimersnewstoday.com/news/fda-mulls-expanded-home-injectionsalzheimers-drug-leqembi/?utm_source=openai))

If a week brings few truly new, treatment‑relevant developments, I will keep sections brief rather than repeat prior items.
